Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Journey Medical (DERM) Income towards Parent Company: 2020-2024

Historic Income towards Parent Company for Journey Medical (DERM) over the last 5 years, with Dec 2024 value amounting to -$14.7 million.

  • Journey Medical's Income towards Parent Company rose 3.14% to -$2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.5 million, marking a year-over-year increase of 53.41%. This contributed to the annual value of -$14.7 million for FY2024, which is 280.79% down from last year.
  • According to the latest figures from FY2024, Journey Medical's Income towards Parent Company is -$14.7 million, which was down 280.79% from -$3.9 million recorded in FY2023.
  • In the past 5 years, Journey Medical's Income towards Parent Company registered a high of $4.9 million during FY2020, and its lowest value of -$44.0 million during FY2021.
  • Over the past 3 years, Journey Medical's median Income towards Parent Company value was -$14.7 million (recorded in 2024), while the average stood at -$16.1 million.
  • As far as peak fluctuations go, Journey Medical's Income towards Parent Company tumbled by 989.13% in 2021, and later surged by 87.00% in 2023.
  • Over the past 5 years, Journey Medical's Income towards Parent Company (Yearly) stood at $4.9 million in 2020, then slumped by 989.13% to -$44.0 million in 2021, then spiked by 32.65% to -$29.6 million in 2022, then spiked by 87.00% to -$3.9 million in 2023, then plummeted by 280.79% to -$14.7 million in 2024.